Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $455,284.08 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 27,493 shares of Tyra Biosciences stock in a transaction on Friday, November 1st. The shares were sold at an average price of $16.56, for a total transaction of $455,284.08. Following the completion of the sale, the director now owns 458,506 shares in the company, valued at approximately $7,592,859.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tyra Biosciences Stock Down 1.7 %

Tyra Biosciences stock opened at $16.39 on Monday. The company’s 50-day moving average price is $22.39 and its 200-day moving average price is $19.92. Tyra Biosciences, Inc. has a twelve month low of $10.60 and a twelve month high of $29.60. The company has a market cap of $865.49 million, a PE ratio of -9.70 and a beta of 1.08.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. As a group, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on TYRA shares. HC Wainwright lifted their price target on shares of Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, October 28th. Wedbush reiterated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Oppenheimer lifted their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Piper Sandler initiated coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price on the stock. Finally, Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Buy” and a consensus price target of $31.40.

Hedge Funds Weigh In On Tyra Biosciences

A number of large investors have recently made changes to their positions in the company. RA Capital Management L.P. boosted its stake in shares of Tyra Biosciences by 43.9% during the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares during the period. BVF Inc. IL boosted its stake in shares of Tyra Biosciences by 70.1% during the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after purchasing an additional 338,208 shares during the period. Vanguard Group Inc. boosted its stake in shares of Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after purchasing an additional 140,833 shares during the period. Finally, Kynam Capital Management LP boosted its stake in shares of Tyra Biosciences by 51.4% during the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after purchasing an additional 175,000 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.